vTv Therapeutics (NASDAQ:VTVT) Stock Price Passes Below Fifty Day Moving Average – Here’s What Happened

vTv Therapeutics Inc. (NASDAQ:VTVT)’s share price passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $14.95 and traded as low as $14.01. vTv Therapeutics shares last traded at $14.01, with a volume of 3,394 shares traded.

Analyst Ratings Changes

Separately, Alliance Global Partners assumed coverage on shares of vTv Therapeutics in a research report on Monday, December 9th. They issued a “buy” rating and a $35.00 price objective for the company.

vTv Therapeutics Stock Performance

The stock has a 50 day moving average price of $14.95 and a 200 day moving average price of $15.69. The company has a market capitalization of $44.69 million, a P/E ratio of -3.09 and a beta of 0.69.

Institutional Trading of vTv Therapeutics

An institutional investor recently bought a new position in vTv Therapeutics stock. FMR LLC purchased a new position in vTv Therapeutics Inc. (NASDAQ:VTVT) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 178,200 shares of the biotechnology company’s stock, valued at approximately $2,402,000. FMR LLC owned 5.92% of vTv Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 17.51% of the company’s stock.

vTv Therapeutics Company Profile

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.